Clinical Policy: Pancrelipase (Creon, Pancreaze, Pertzye, Viokace, Zenpep)
Customize your policy alerts
Sign up for Ambetter Nevada Policy CP.PCH.44 alerts
Get alerted when Policy CP.PCH.44 changes without checking for updates manually.
Monitor payer policy activity
This policy governs commercial-plan coverage and prior authorization for pancrelipase products when documented clinical, step-therapy, product-specific, and dosing criteria are met for exocrine pancreatic insufficiency.
The maximum dose criterion was revised to include 10,000 lipase units per kilogram per day in accordance with prescribing information.
Commercial requests for Pertzye or Viokace now require failure of Pancreaze, Creon, and Zenpep.
Pancreaze requests are now subject to redirection to Creon and Zenpep.
Examples of positive response for continuation therapy were added, including reduced steatorrhea and gastrointestinal symptoms, gains in weight or muscle measures, and improved fat-soluble vitamin levels.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.